RhumbLine Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.4M | Buy |
157,794
+13
| +0% | +$8.85K | 0.07% | 222 |
|
|
2026
Q1 | $122M | Sell |
157,781
-3,024
| -2% | -$2.32M | 0.1% | 169 |
|
|
2025
Q4 | $124M | Sell |
160,805
-7,196
| -4% | -$4.89M | 0.1% | 162 |
|
|
2025
Q3 | $94.5M | Sell |
168,001
-2,658
| -2% | -$1.5M | 0.08% | 213 |
|
|
2025
Q2 | $89.6M | Sell |
170,659
-2,508
| -1% | -$1.4M | 0.08% | 213 |
|
|
2025
Q1 | $110M | Buy |
173,167
+2,547
| +1% | +$1.75M | 0.1% | 166 |
|
|
2024
Q4 | $122M | Sell |
170,620
-4,126
| -2% | -$3.46M | 0.11% | 148 |
|
|
2024
Q3 | $184M | Sell |
174,746
-5,351
| -3% | -$5.95M | 0.17% | 106 |
|
|
2024
Q2 | $189M | Sell |
180,097
-3,470
| -2% | -$3.36M | 0.18% | 95 |
|
|
2024
Q1 | $177M | Buy |
183,567
+1,969
| +1% | +$1.87M | 0.17% | 104 |
|
|
2023
Q4 | $159M | Sell |
181,598
-1,680
| -0.9% | -$1.38M | 0.17% | 105 |
|
|
2023
Q3 | $151M | Sell |
183,278
-2,795
| -2% | -$2.2M | 0.18% | 100 |
|
|
2023
Q2 | $134M | Buy |
186,073
+2,369
| +1% | +$1.83M | 0.15% | 112 |
|
|
2023
Q1 | $151M | Sell |
183,704
-4,201
| -2% | -$3.17M | 0.19% | 97 |
|
|
2022
Q4 | $136M | Buy |
187,905
+8,907
| +5% | +$6.57M | 0.18% | 107 |
|
|
2022
Q3 | $123M | Buy |
178,998
+5,425
| +3% | +$3.41M | 0.18% | 98 |
|
|
2022
Q2 | $103M | Buy |
173,573
+10,447
| +6% | +$6.79M | 0.15% | 125 |
|
|
2022
Q1 | $114M | Buy |
163,126
+1,127
| +0.7% | +$713K | 0.15% | 120 |
|
|
2021
Q4 | $102M | Buy |
161,999
+732
| +0.5% | +$450K | 0.13% | 140 |
|
|
2021
Q3 | $97.6M | Sell |
161,267
-525
| -0.3% | -$326K | 0.13% | 131 |
|
|
2021
Q2 | $90.4M | Sell |
161,792
-3,458
| -2% | -$1.75M | 0.12% | 147 |
|
|
2021
Q1 | $78.2M | Sell |
165,250
-8,624
| -5% | -$4.2M | 0.11% | 157 |
|
|
2020
Q4 | $84M | Sell |
173,874
-19,004
| -10% | -$10.3M | 0.12% | 148 |
|
|
2020
Q3 | $108M | Sell |
192,878
-3,019
| -2% | -$1.83M | 0.17% | 112 |
|
|
2020
Q2 | $122M | Buy |
195,897
+49,448
| +34% | +$28.1M | 0.2% | 92 |
|
|
2020
Q1 | $71.5M | Buy |
146,449
+387
| +0.3% | +$160K | 0.15% | 136 |
|
|
2019
Q4 | $54.8M | Buy |
146,062
+4,581
| +3% | +$1.54M | 0.09% | 204 |
|
|
2019
Q3 | $39.2M | Buy |
141,481
+6,372
| +5% | +$1.89M | 0.07% | 251 |
|
|
2019
Q2 | $42.3M | Buy |
135,109
+2,289
| +2% | +$762K | 0.08% | 224 |
|
|
2019
Q1 | $54.5M | Sell |
132,820
-14,415
| -10% | -$5.94M | 0.11% | 181 |
|
|
2018
Q4 | $55M | Buy |
147,235
+1,104
| +0.8% | +$404K | 0.12% | 162 |
|
|
2018
Q3 | $59M | Sell |
146,131
-1,338
| -0.9% | -$509K | 0.11% | 179 |
|
|
2018
Q2 | $50.9M | Buy |
147,469
+4,098
| +3% | +$1.28M | 0.1% | 193 |
|
|
2018
Q1 | $49.4M | Buy |
143,371
+148
| +0.1% | +$51.5K | 0.1% | 198 |
|
|
2017
Q4 | $53.8M | Buy |
143,223
+7,939
| +6% | +$3.22M | 0.11% | 188 |
|
|
2017
Q3 | $60.5M | Buy |
135,284
+2,030
| +2% | +$966K | 0.13% | 160 |
|
|
2017
Q2 | $65.4M | Buy |
133,254
+2,122
| +2% | +$929K | 0.15% | 138 |
|
|
2017
Q1 | $50.8M | Buy |
131,132
+2,824
| +2% | +$1.05M | 0.12% | 172 |
|
|
2016
Q4 | $47.1M | Buy |
128,308
+2,179
| +2% | +$829K | 0.12% | 178 |
|
|
2016
Q3 | $50.7M | Buy |
126,129
+3,200
| +3% | +$1.28M | 0.14% | 147 |
|
|
2016
Q2 | $42.9M | Buy |
122,929
+4,439
| +4% | +$1.71M | 0.13% | 160 |
|
|
2016
Q1 | $42.7M | Buy |
118,490
+4,356
| +4% | +$1.79M | 0.13% | 153 |
|
|
2015
Q4 | $62M | Buy |
114,134
+2,873
| +3% | +$1.56M | 0.2% | 100 |
|
|
2015
Q3 | $51.8M | Buy |
111,261
+3,596
| +3% | +$1.93M | 0.18% | 115 |
|
|
2015
Q2 | $54.9M | Sell |
107,665
-19,126
| -15% | -$9.33M | 0.18% | 114 |
|
|
2015
Q1 | $57.2M | Sell |
126,791
-1,386
| -1% | -$587K | 0.17% | 129 |
|
|
2014
Q4 | $52.6M | Sell |
128,177
-3,381
| -3% | -$1.33M | 0.15% | 145 |
|
|
2014
Q3 | $47.4M | Sell |
131,558
-4,946
| -4% | -$1.66M | 0.14% | 151 |
|
|
2014
Q2 | $38.6M | Sell |
136,504
-4,249
| -3% | -$1.26M | 0.11% | 183 |
|
|
2014
Q1 | $42.3M | Buy |
140,753
+931
| +0.7% | +$287K | 0.13% | 170 |
|
|
2013
Q4 | $38.5M | Sell |
139,822
-2,800
| -2% | -$805K | 0.11% | 177 |
|
|
2013
Q3 | $44.6M | Sell |
142,622
-2,226
| -2% | -$586K | 0.14% | 151 |
|
|
2013
Q2 | $32.6M | Buy |
+144,848
| New | +$33.7M | 0.1% | 183 |
|
Other funds holding REGN
RhumbLine Advisers's REGN Position: Q2 2026 in Review
RhumbLine Advisers increased its Regeneron Pharmaceuticals (REGN) stake by 0.01% in Q2 2026, buying an estimated $8.85K and bringing the position to 157,794 shares worth $98.4M. The position accounts for 0.07% of the portfolio, ranked #222.
RhumbLine Advisers first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $189M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- RhumbLine Advisers held 157,794 shares of Regeneron Pharmaceuticals worth $98.4M as of Q2 2026.
- RhumbLine Advisers bought 13 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
- Regeneron Pharmaceuticals made up 0.07% of RhumbLine Advisers's portfolio in Q2 2026, its #222 holding.
- RhumbLine Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Regeneron Pharmaceuticals position peaked at $189M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.